Drugs Containing Excipient (Inactive Ingredient) HYMETELLOSE

Branded drugs containing HYMETELLOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	HYMETELLOSE	2026-02-13

Generic drugs containing HYMETELLOSE excipient

Company	Ingredient	NDC	Excipient
Novartis Pharmaceuticals Corporation	triclabendazole	0078-0937	HYMETELLOSE

Hymetellose Market Dynamics, Patent Position and Financial Trajectory

Last updated: September 26, 2026

Hymetellose is best analyzed as hypromellose, also called hydroxypropyl methylcellulose or HPMC, a cellulose-derived pharmaceutical excipient used in tablets, capsules, coatings, ophthalmic products, controlled-release systems and semisolid formulations. The term “Hymetellose” is not the dominant pharmacopoeial or commercial name in major public databases. Market data therefore is reported under hypromellose, HPMC or hydroxypropyl methylcellulose.

The market has stable demand, low therapeutic substitution risk and moderate supplier concentration. Volume growth is tied to generic-drug production, oral solid dosage expansion, vegetarian capsule adoption and modified-release formulations. Pricing power is stronger for narrow-viscosity grades, low-substitution grades, ophthalmic grades and validated pharmaceutical-quality material than for standard tablet-grade HPMC.

What is Hymetellose used for in pharmaceutical manufacturing?

Hymetellose is a multifunctional excipient with several pharmaceutical roles:

Application	Function	Commercial importance
Tablet binder	Improves granule and tablet cohesion	High
Film coating	Forms a uniform protective and cosmetic film	High
Controlled release	Creates a hydrated polymer matrix	High
Capsule shell	Provides a plant-derived alternative to gelatin	High
Ophthalmic products	Increases viscosity and ocular residence time	Medium
Suspension stabilizer	Controls sedimentation and rheology	Medium
Taste masking	Supports polymeric coating systems	Medium
Mucoadhesive delivery	Extends contact time at mucosal surfaces	Emerging

HPMC is available in multiple viscosity grades and substitution profiles. The grade determines hydration rate, gel strength, film performance, compression behavior and drug-release kinetics. A formulation developed around one grade may require substantial reformulation and regulatory work if a sponsor changes supplier or viscosity specification.

The principal demand driver is oral solid dosage manufacturing. HPMC is present in both high-volume generic products and higher-margin modified-release products. Controlled-release applications generally have greater switching costs because polymer grade, particle size, viscosity and processing conditions affect dissolution performance.

How large is the hypromellose excipient market?

Public companies do not generally disclose revenue from hypromellose as a separate line item. Market estimates vary because some reports include pharmaceutical HPMC only, while others combine pharmaceutical, food, construction and industrial cellulose ethers.

The pharmaceutical segment is structurally smaller than the total HPMC market but has higher average selling prices and more demanding quality requirements. Pharmaceutical HPMC competes on:

• Pharmacopoeial compliance
• Batch-to-batch viscosity consistency
• Traceability
• Microbial and endotoxin controls
• Regulatory documentation
• Supply continuity
• Technical support
• Validated manufacturing history

The broader market has a low-to-mid-single-digit long-term volume-growth profile. Pharmaceutical demand is supported by generic-drug volume, expansion of modified-release dosage forms and continued use of non-gelatin capsules. Revenue growth can exceed volume growth when customers move toward specialty grades or when manufacturers pass through energy, labor and raw-material costs.

What drives Hymetellose pricing?

Pricing is determined by grade, substitution ratio, viscosity, particle size, packaging, region, qualification status and order volume. Standard tablet and coating grades face greater competition than specialty controlled-release or ophthalmic grades.

The principal cost inputs are refined cellulose, propylene oxide, methyl chloride, utilities, labor, packaging, quality control and compliance. Manufacturing is capital-intensive because the process requires controlled etherification, purification, drying, milling and classification.

Pricing pressure is strongest in China and India, where multiple suppliers compete on standard grades. Pricing is more resilient in the United States, Europe and Japan when a supplier has an approved manufacturing site, a long customer qualification history and an established regulatory file.

Which companies manufacture pharmaceutical hypromellose?

The main global suppliers and relevant product families include:

Company	Relevant HPMC or cellulose-ether brands	Market position
Shin-Etsu Chemical	Pharmacoat, Metolose, AQOAT	Major pharmaceutical-grade supplier
IFF, formerly Dow-related cellulose businesses	METHOCEL, ETHOCEL and related polymers	Major global excipient supplier
Ashland	Benecel and related cellulose ethers	Global specialty excipient supplier
JRS Pharma	Vivapur and cellulose-based excipients	Strong oral solid dosage presence
Roquette	LYCATAB and broader excipient portfolio	Broad formulation and excipient platform
Zhejiang recorded suppliers	Multiple HPMC grades	Cost-competitive regional supply
Indian manufacturers	Pharmaceutical HPMC and cellulose ethers	Growing generic-drug supply base

Brand ownership and product portfolios have changed through acquisitions and divestitures. HPMC should be evaluated at the manufacturing-site and grade level rather than only by corporate parent.

Shin-Etsu has particular relevance because its Pharmacoat and AQOAT products are widely associated with pharmaceutical film coating and controlled-release applications. IFF and Ashland compete through broad excipient portfolios, formulation support and global customer qualification.

How strong is the patent estate for Hymetellose?

The basic HPMC composition is mature and is not protected by a meaningful composition-of-matter patent estate. HPMC has been used commercially for decades, and core composition patents associated with ordinary pharmaceutical use are generally expired.

The commercially relevant intellectual-property barriers are narrower:

1. Manufacturing processes that improve substitution uniformity, purity or viscosity control.
2. Particle engineering and granulation technologies.
3. Coating systems combining HPMC with plasticizers, pigments or functional polymers.
4. Controlled-release matrices using specific polymer combinations.
5. Proprietary premixes and ready-to-use coating systems.
6. Manufacturing equipment and process-control methods.
7. Trademarks and quality documentation.
8. Customer-specific regulatory and formulation know-how.

No single patent number can be assigned to “Hymetellose” as a product category without identifying the manufacturer, grade and jurisdiction. Patent searches must distinguish the HPMC substance from a finished dosage-form patent that merely claims HPMC as one component.

What formulations are protected by HPMC patents?

Patent protection is more likely to cover a drug product or delivery system than HPMC itself. Relevant claims may cover:

• A controlled-release tablet containing a specified percentage of HPMC.
• A multilayer tablet with an HPMC matrix.
• A coating composition containing HPMC and a plasticizer.
• A drug-polymer ratio that produces a defined dissolution profile.
• An ophthalmic formulation containing HPMC at a specified concentration.
• A capsule or tablet manufacturing process using a selected HPMC grade.

These patents can affect generic entry even when the excipient itself is unpatented. A generic applicant may design around the claim by changing polymer concentration, using another hydrophilic polymer, modifying tablet geometry or selecting a different release mechanism.

What is the FDA regulatory status of hypromellose?

Hypromellose is an established pharmaceutical excipient recognized in major compendia, including the United States Pharmacopeia-National Formulary, European Pharmacopoeia and Japanese Pharmacopoeia. FDA’s Inactive Ingredient Database lists hypromellose across multiple dosage forms and routes, subject to concentration and product-specific conditions.[1]

FDA does not approve excipients through the same premarket process used for active pharmaceutical ingredients. Sponsors remain responsible for demonstrating that the excipient is suitable for the intended formulation, route, concentration and manufacturing process.

Regulatory value comes from:

• Compendial compliance
• A qualified manufacturing site
• Change-control procedures
• Drug Master File support where applicable
• Consistent impurity profile
• Extractables and leachables data
• Microbial controls
• Stability data
• Supply-chain traceability

A supplier’s regulatory position can create a commercial moat even where patent protection is weak. Switching suppliers may trigger comparative testing, stability work, process validation and regulatory notification.

What is the Orange Book status of Hymetellose?

Hymetellose or hypromellose is not an active pharmaceutical ingredient with an independent Orange Book exclusivity position. It does not receive standalone New Chemical Entity exclusivity, patent-term restoration or Orange Book listing as a drug product.

Orange Book risk arises at the finished-drug level. A drug containing HPMC may have listed patents covering the active ingredient, formulation, dosage form or method of use. Those patents belong to the finished product sponsor, not automatically to the HPMC supplier.

A generic applicant using HPMC may therefore face Paragraph IV litigation involving the branded drug, but the dispute will ordinarily concern the drug product claims. HPMC itself does not create a generic-delay mechanism.

When does Hymetellose lose exclusivity?

Hymetellose has no relevant standalone regulatory exclusivity period. Its core substance is a mature excipient.

Commercial exclusivity can still persist through:

• Proprietary viscosity and substitution profiles
• Customer qualification
• Long-term supply agreements
• Pharmaceutical-grade manufacturing approvals
• Technical know-how
• Process patents
• Trademark recognition
• Formulation-specific performance
• Regulatory history at a particular site

This distinction matters financially. A new producer may be able to manufacture chemically similar HPMC but still face a lengthy qualification period before competing for regulated pharmaceutical business.

Which companies are challenging the HPMC market leaders?

Competition is increasing from Chinese and Indian suppliers, especially in standard grades used for tablet binding and film coating. The competitive threat is lower in highly qualified controlled-release, ophthalmic and specialty coating grades.

The market has four competitive layers:

Layer	Competitive basis	Entry difficulty
Commodity industrial HPMC	Price and capacity	Low to moderate
Standard pharmaceutical HPMC	Compendial quality and consistency	Moderate
Specialty pharmaceutical HPMC	Performance, documentation and qualification	High
Formulation systems and premixes	Product performance and customer integration	High

Asian producers are most likely to pressure prices in standard grades. Established Japanese, U.S. and European suppliers retain advantages in documentation, technical support and multinational qualification.

What patent litigation affects Hymetellose?

No broad patent-litigation pattern attaches to hypromellose as an excipient category. Litigation is more likely to arise in three settings:

1. Branded-drug litigation involving an HPMC-containing formulation.
2. Disputes over controlled-release dosage-form claims.
3. Trade-secret or contract disputes involving manufacturing specifications, process conditions or customer formulas.

Paragraph IV challenges generally target Orange Book-listed patents for the finished drug. A generic manufacturer’s use of HPMC may be relevant to infringement analysis only if the asserted claims specify a particular polymer, concentration, viscosity or release profile.

Standalone excipient patent litigation is less common than finished-product litigation because the basic HPMC composition is mature and widely available.

What manufacturing and intellectual-property barriers exist?

The key barriers are process control and regulatory execution rather than basic chemistry.

Manufacturers must control substitution uniformity, viscosity distribution, moisture, residual solvents, particle-size distribution, microbial burden and batch consistency. Small changes can affect tablet hardness, coating defects, dissolution and release kinetics.

The highest-value manufacturing capabilities include:

• Narrow viscosity specifications
• Consistent hydroxypropyl and methoxyl substitution
• Low-ash and low-impurity profiles
• Controlled particle morphology
• Reliable scale-up
• Pharmaceutical-grade documentation
• Multiple qualified production sites
• Regulatory change management

These factors create a qualification barrier. A supplier that passes initial testing may still fail to displace an incumbent if the customer is unwilling to repeat stability, dissolution and process-validation work.

How does Hymetellose compare with competing excipients?

Excipient	Primary advantage	Limitation versus HPMC
Hydroxypropyl cellulose	Strong film formation and solubility	Different gel and release behavior
Sodium carboxymethylcellulose	High viscosity and binding	Ionic behavior can limit compatibility
Povidone	Strong binder and broad solubility	Less suitable for some sustained-release matrices
Ethylcellulose	Strong water-insoluble barrier	Requires different release design
Polyethylene oxide	High-viscosity controlled release	Different processing and oxidative-stability profile
Gelatin	Established capsule technology	Animal origin and cross-linking concerns
Pullulan	Plant-derived capsule and film option	Higher cost and narrower supply base

HPMC’s commercial strength comes from its balance of functionality, regulatory acceptance, supply availability and compatibility with common tablet and capsule processes.

What is the financial trajectory for Hymetellose suppliers?

Financial performance is likely to follow a mixed trajectory:

• Volume growth should remain steady because HPMC is embedded in generic and branded formulations.
• Standard-grade margins will face pressure from Asian capacity additions.
• Specialty-grade margins should remain stronger because qualification and switching costs are higher.
• Energy and cellulose costs will create periodic margin volatility.
• Revenue growth will be supported by controlled-release formulations, vegetarian capsules and pharmaceutical outsourcing.
• Supplier consolidation may improve pricing discipline and technical-service scale.

HPMC revenue is usually reported inside broader specialty-materials, cellulose-derivatives or pharmaceutical-excipients segments. Public filings generally do not isolate Hymetellose or hypromellose sales. Financial analysis should therefore use segment-level indicators such as excipient revenue, cellulose-ether volume, operating margin, plant investment and capacity expansion.

A supplier with a large pharmaceutical customer base can produce more stable earnings than one focused on industrial construction grades. Pharmaceutical customers typically value continuity and quality over the lowest spot price, but procurement organizations can impose annual price reductions after qualification.

What revenue exposure exists for drug manufacturers?

For a drug manufacturer, HPMC is usually a low-cost component but a high-consequence supply input. Excipient cost may represent a small share of finished-product cost, while a shortage or failed batch can interrupt production.

Revenue exposure is highest when:

• One HPMC grade is used across many products.
• The supplier is single-sourced.
• The products use narrow dissolution specifications.
• The formulations are controlled release.
• Regulatory filings identify a specific grade or supplier.
• The products have limited manufacturing redundancy.

A supply disruption can create disproportionate financial exposure relative to the excipient’s purchase price.

What generic launch risks exist for HPMC-containing products?

Generic launch risk is determined primarily by the finished drug’s patent and regulatory position, not by HPMC ownership.

Key risks include:

• Orange Book formulation patents
• Method-of-use patents
• Controlled-release claims
• Dissolution-profile requirements
• Inability to substitute the HPMC grade without reformulation
• Supplier change-control delays
• Manufacturing-site qualification
• FDA questions regarding inactive ingredients
• Paragraph IV litigation and a possible 30-month stay

A generic sponsor can usually source HPMC from multiple suppliers, but equivalent performance must be demonstrated. For modified-release products, changing viscosity grade or polymer particle size may materially alter release kinetics.

What are the geographic coverage and supply-chain risks?

North America and Europe remain high-value pharmaceutical markets, while China and India are important production and growth centers. Japan retains a strong position in high-quality cellulose-derivative manufacturing and technical-grade specialization.

Geographic risks include:

• Concentration of production in East Asia
• Port and freight disruption
• Energy-price volatility
• Cellulose availability
• Export controls or customs delays
• Regulatory inspection findings
• Single-site qualification
• Regional pharmacopoeial differences

Multinational drug companies increasingly seek dual sourcing, regional inventory and prequalified alternate grades. That trend favors suppliers with multiple sites and strong technical documentation.

Key Takeaways

• Hymetellose is best treated as hypromellose, HPMC or hydroxypropyl methylcellulose.
• The substance is a mature excipient with no meaningful standalone regulatory exclusivity.
• Core HPMC composition patents are generally expired; current IP value lies in processes, specialty grades, formulations and know-how.
• Pharmaceutical-grade HPMC has stronger pricing and customer retention than industrial or standard-grade material.
• Demand is linked to generic tablets, film coating, controlled-release products and vegetarian capsules.
• The main competitive threat is price pressure from Chinese and Indian suppliers in standard grades.
• The main commercial moat is qualification, quality consistency, regulatory documentation and technical support.
• Orange Book and Paragraph IV risk attaches to finished drugs containing HPMC, not to HPMC itself.
• Financial exposure is concentrated in specialty-grade suppliers and drug manufacturers dependent on a single qualified HPMC source.
• Public financial statements generally do not report Hymetellose revenue separately.

FAQs

Is Hymetellose the same as hypromellose?

Yes. Hymetellose is generally used to refer to hypromellose, also known as HPMC or hydroxypropyl methylcellulose. Exact identity should be confirmed against the supplier’s specification and pharmacopoeial designation.

Is hypromellose a pharmaceutical active ingredient?

No. Hypromellose is an inactive pharmaceutical ingredient used as a binder, coating polymer, capsule material, viscosity modifier and controlled-release matrix former.

Can a pharmaceutical company freely switch HPMC suppliers?

No. A switch may require comparative testing, dissolution studies, stability work, process validation and regulatory assessment. The burden is higher for modified-release and ophthalmic products.

Does HPMC create a Paragraph IV patent challenge?

No. HPMC itself does not create Paragraph IV exposure. Paragraph IV risk arises when an ANDA applicant challenges patents listed for the finished branded drug.

Which HPMC grades have the strongest commercial value?

Specialty controlled-release grades, ophthalmic grades, narrow-viscosity grades, low-substitution grades and ready-to-use coating systems generally have greater commercial value than standard tablet-grade HPMC.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.
3. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.
4. Shin-Etsu Chemical Co., Ltd. (n.d.). Pharmaceutical excipients and cellulose derivatives. https://www.shinetsu.co.jp
5. International Pharmaceutical Excipients Council. (2017). The IPEC excipient composition guidelines. IPEC.
6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm